



PRESS RELEASE

MaxiVAX appoints T. Scott Johnson, M.D., As New Board Director

- **Board strengthened as MaxiVAX prepares for next growth phase**
- **Johnson brings strong background in medicine and company management**

Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of T. Scott Johnson, M.D., as a Board Director. Dr Johnson was a Founder of The Medicines Company where he is currently Chief Medical Advisor and Vice President of Business Development. He is also a Founder and General Partner of JSB Partners, L.P., providing specialized investment banking and advisory services to biotechnology and pharmaceutical companies.

Bernard Mach, MaxiVAX Executive Chairman, commented: “We are delighted that Dr. Johnson has joined our Board of Directors. His extensive experience in medicine, company management and capital formation brings a new dimension to MaxiVAX. This is especially important as we accelerate our next phase of growth.”

Dr Johnson said: “I am pleased and excited to join MaxiVAX’s highly talented team. As a physician, I am keenly interested in the company’s novel approach to immuno-oncology, a very promising therapeutic field in the battle against cancer. I look forward to helping the company achieve its ambitious growth plans.”

Other Board members include Clarence Peter, partner in the Swiss law firm Python, and Jack Barbut, the former Chief Executive of Novimmune.

MaxiVAX received the 2017 CTI Swiss Medtech Award on 13 June 2017 from Swiss Federal Councillor Johann N. Schneider-Amman. This recognised the work done by both MaxiVAX and Prof. Nicolas Mach of Geneva University Hospitals, who is the company’s Chief Scientific Officer. The company’s novel Immuno-Oncology therapeutic vaccination MVX-ONCO-1 was selected live as the winning project by about 600 representatives of the sector who attended Swiss Medtech Day.

The company has successfully completed a phase I trial with MVX-ONCO-1 in 25 patients with a range of cancer types at an advanced stage, when no serious adverse events were reported in the study drug. The product is now in phase II development.

T. Scott Johnson, M.D.

Dr Johnson brings 40 years of experience in medicine, venture capital and investment banking. He was a Founder of The Medicines Company in 1996, where he is currently Chief Medical Advisor and Vice President of Business Development. Since 1999 he has been a Founder and General Partner of JSB Partners, L.P. Prior to this, he was President and Managing Director of MPM Capital Advisors and Founder and Senior Managing Director of Medical Portfolio Management, Inc. His medical career includes serving as an Associate Professor of Medicine at the University of South Alabama College of Medicine and Assistant Professor of Medicine, Harvard Medical School, in connection with the Boston-based Brigham and Women's and Beth Israel Hospitals. He also served as Resident in Internal Medicine and as Chief Resident in Medicine at Beth Israel, and as a Fellow in Pulmonary Disease and Critical Care Medicine at the University of Colorado Medical Center. Dr. Johnson earned his Bachelor of Science degree in Chemistry at the University of Alabama. He went on to the University of Alabama College of Medicine, where he earned his medical degree and received the Dean's Award for Most Outstanding Graduate of his class. He has the Board of Medical Examiners Certification for Internal Medicine, Pulmonary Diseases and Critical Care Medicine and is registered to practice medicine in Alabama and Massachusetts.

About MVX-ONCO-1

MaxiVAX's novel Immuno-Oncology therapeutic vaccination is based on triggering the patient's own natural immune response mechanism via an innovative and proprietary technology in order to eliminate cancer cells. MVX-ONCO-1 has been classified as an Advanced Therapeutic Medicinal Product by the European Medicines Agency (EMA).

MVX-ONCO-1 is a product that contains two distinct biological entities:

1) Vaccine: administered by sub-cutaneous injection, using the patient's own irradiated cancer cells as vaccine antigens, with a key benefit of using the entire set of tumor antigens from the patient's own cells.

2) Immune boosting agent: an immune boosting agent (GM-CSF: granulocyte macrophage- colony stimulating factor) is delivered at the site of vaccination in a sustained manner, via genetically reprogrammed cells, encapsulated in a small biocompatible capsule. Two capsules, which are essential to protect the GM-CSF producing cells, are placed underneath the skin at the same site as the vaccine injection. After 1 week the capsules are removed.

The treatment is repeated for a total of 6 immunizations over a period of 8 weeks.

This innovative technology of protein delivery by encapsulated cells was pioneered by Prof. P. Aebischer, former President of EPFL in Lausanne, who has been an advisor to MaxiVAX since its foundation.

About MaxiVAX www.maxivax.ch

MaxiVAX is a private Swiss clinical-stage biotech company with a novel, patient-specific and personalized active immunotherapy treatment for cancer. The company received the 2017 CTI Swiss Medtech Award for its ground-breaking approach.

Its lead product MVX-ONCO-1 combines a vaccination process against the complete tumor cell with an immune system-boosting agent, provided in a sustained manner. This unique combination triggers a protective immune response against multiple cancer types. MVX-ONCO-1 has completed a phase I trial in patients suffering from various solid cancers at an advanced stage. This trial confirmed a benign safety profile with encouraging efficacy data, and the product is now in phase II development.

Investor and Business Development Contact

Dimitrios Goundis Ph.D.

CEO

dgoundis@maxivax.ch

+41 22 552 26 13

MaxiVAX SA

Rue de l'Athénée 24

CH-1206 Geneva, Switzerland

Media Contact

Nick Miles / Toomas Kull

Cabinet Privé de Conseils s.a.

Genève, Suisse

Téléphone : +41 22 552 46 46

Mobile : +41 79 678 76 26

E-mail : miles@cpc-pr.com

kull@cpc-pr.com

Edward Agne

The Communications Strategy Group Inc.

Cambridge, Massachusetts, États-Unis

Téléphone : +1 781 631 3117

Mobile : +1 781 888 0099

E-mail : edagne@comstratgroup.com